MURA (Mural Oncology) Common Stock : $0.17 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Mural Oncology Common Stock?

Mural Oncology's quarterly common stock increased from Jun. 2024 ($0.17 Mil) to Sep. 2024 ($0.17 Mil) and increased from Sep. 2024 ($0.17 Mil) to Dec. 2024 ($0.17 Mil).

Mural Oncology's annual common stock increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.17 Mil) and increased from Dec. 2023 ($0.17 Mil) to Dec. 2024 ($0.17 Mil).

Mural Oncology Common Stock Historical Data

The historical data trend for Mural Oncology's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mural Oncology Common Stock Chart

Mural Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Common Stock

0.17

Mural Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Common Stock	Get a 7-Day Free Trial						0.17	0.17	0.17	0.17	0.17

Mural Oncology Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Mural Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mural Oncology PLC (NAS:MURA) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380

Website

https://www.muraloncology.com

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.